UK MHRA revokes Valneva chikungunya vaccine IXCHIQ marketing authorization after benefit-risk review

• UK regulator MHRA revoked the UK marketing authorization for Valneva’s chikungunya vaccine IXCHIQ following a benefit-risk reassessment by CHM.
• Decision relied on previously reviewed safety data; no new safety signal cited.
• Revocation does not affect IXCHIQ licenses in the EU, Canada, Brazil, or other markets where it is sold.
• Product has not been actively distributed in the UK for months due to low traveler demand; no recall costs expected.
• Valneva will not appeal, citing immaterial financial impact while prioritizing expansion in endemic markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valneva SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610071600PRIMZONEFULLFEED1001276807) on October 07, 2026, and is solely responsible for the information contained therein.